Are Established Embedded Performance Validity Test Cut-Offs Generalizable to Patients With Multiple Sclerosis? | Zendy

Christopher H. Domen | Zendy; Michael R. Greher | Zendy; Patrick Hosokawa | Zendy; Sierra L Barnes | Zendy; Brian Hoyt | Zendy; Thomas R. Wodushek | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Are Established Embedded Performance Validity Test Cut-Offs Generalizable to Patients With Multiple Sclerosis?

Author(s) -

Christopher H. Domen,

Michael R. Greher,

Patrick Hosokawa,

Sierra L Barnes,

Brian Hoyt,

Thomas R. Wodushek

Publication year - 2020

Publication title -

archives of clinical neuropsychology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.909

H-Index - 98

eISSN - 1873-5843

pISSN - 0887-6177

DOI - 10.1093/arclin/acaa016

Subject(s) - multiple sclerosis , sample size determination , medicine , relapsing remitting , sample (material) , cut off , statistics , psychiatry , mathematics , chemistry , chromatography , power (physics) , physics , quantum mechanics

Data for the use of embedded performance validity tests (ePVTs) with multiple sclerosis (MS) patients are limited. The purpose of the current study was to determine whether ePVTs previously validated in other neurological samples perform similarly in an MS sample.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research